As cancer has had an impact with one of our family members (luckily not stage 3+) I'm always interested in being aware of the latest cancer treatments.This is especially the case when you need to attend out of hours meetings with oncologists at the expense of your normal life. Note that on the other hand it is unfortunately a different case if the patient can't afford the treatment from experience with another acquaintance who was on Centrelink - even though I was willing to stump up some of the payments. In either case, this does highlight the importance of cancer treatments to the medical sector possibly above all else.
Anyway, back to Imugene. The straws on Imugene by slymeat and slats especially help in giving a overview of the state of play.
Unlike Telix and Clarity, Imugene seems to be taking a more radical path of using immunotherapy to kill cancer cells (one case uses an "engineered virus"). This eliminates the issues in the acquisition and costs of radioisotopes for targeted radiotherapy. Paul Hopper is also on the board and has a large holding.
My only issues are the following:
- Billions of shares on issue
- The timeline to get to Phase 3 trials seem to be missing in the AGM presentation (unless I've missed something).
- The chance Imugene will get booted out of the ASX200. As a reference, the market cap is already below Data#3 and that is not even in the ASX200 yet. Also we have other contenders waiting to dethrone Imugene from the coveted ASX200
Still on my watchlist though. Will be interested to see what happens if Imugene exits the ASX200 and where the price will settle.
